| 42.23 0.63 (1.51%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.87 | 1-year : | 61.75 |
| Resists | First : | 45.27 | Second : | 52.87 |
| Pivot price | 42.51  |
|||
| Supports | First : | 36.76 |
Second : | 31.51 |
| MAs | MA(5) : | 42.31 |
MA(20) : | 41.45 |
| MA(100) : | 34.96 |
MA(250) : | 56.09 |
|
| MACD | MACD : | 2 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 42.5 |
D(3) : | 55 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 116 | Low : | 27.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PCVX ] has closed above bottom band by 42.4%. Bollinger Bands are 40.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.62 - 42.83 | 42.83 - 43.01 |
| Low: | 41.02 - 41.25 | 41.25 - 41.46 |
| Close: | 41.87 - 42.24 | 42.24 - 42.56 |
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Wed, 08 Oct 2025
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) - Insider Monkey
Tue, 07 Oct 2025
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) - Yahoo Finance
Fri, 03 Oct 2025
Vaxcyte’s Strategic Moves: Impact on PCVX - StocksToTrade
Tue, 30 Sep 2025
Vaxcyte to Establish Fill-Finish Manufacturing in North - GlobeNewswire
Tue, 30 Sep 2025
$1 Billion Manufacturing Deal: Vaxcyte Brings Vaccine Production to US with Thermo Fisher Partnership - Stock Titan
Tue, 30 Sep 2025
Vaxcyte signs $1 billion manufacturing deal with Thermo Fisher - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 130 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 117.5 (%) |
| Shares Short | 11,080 (K) |
| Shares Short P.Month | 11,510 (K) |
| EPS | -4.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 23.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -16.5 % |
| Return on Equity (ttm) | -21.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -460 (M) |
| Levered Free Cash Flow | -368 (M) |
| PE Ratio | -10.28 |
| PEG Ratio | 0 |
| Price to Book value | 1.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|